Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy
- 1 March 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 33 (3), 171-187
- https://doi.org/10.2165/11319380-000000000-00000
Abstract
HMG-CoA reductase inhibitors (‘statins’) represent the most effective and widely prescribed drugs currently available for the reduction of low-density lipoprotein cholesterol, a critical therapeutic target for primary and secondary prevention of cardiovascular atherosclerotic disease. In the face of the established lipid lowering and the emerging pleiotropic properties of statins, the patient population suitable for long-term statin treatment is expected to further expand. An overall positive safety and tolerability profile of statins has been established, although adverse events have been reported. Skeletal muscle-related events are the most common adverse events of statin treatment. Statin-induced myopathy can (rarely) manifest with severe and potentially fatal cases of rhabdomyolysis, thus rendering the identification of the underlying predisposing factors critical. The purpose of this review is to summarize the factors that increase the risk of statin-related myopathy. Data from published clinical trials, meta-analyses, postmarketing studies, spontaneous report systems and case reports for rare effects were reviewed. Briefly, the epidemiology, clinical spectrum and molecular mechanisms of statin-associated myopathy are discussed. We further analyse in detail the risk factors that precipitate or increase the likelihood of statin-related myopathy. Individual demographic features, genetic factors and co-morbidities that may account for the significant inter-individual variability in the myopathic risk are presented. Physicochemical properties of statins have been implicated in the differential risk of currently marketed statins. Pharmacokinetic interactions with concomitant medications that interfere with statin metabolism and alter their systemic bioavailability are reviewed. Of particular clinical interest in cases of resistant dyslipidaemia is the interaction of statins with other classes of lipid-lowering agents; current data on the relative safety of available combinations are summarized. Finally, we provide an update of current guidelines for the prevention and management of statin myopathy. The identification of patients with an increased proclivity to statin-induced myopathy could allow more cost-effective approaches of monitoring and screening, facilitate targeted prevention of potential complications, and further improve the already overwhelmingly positive benefit-risk ratio of statins.Keywords
This publication has 126 references indexed in Scilit:
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Statin induced myopathyBMJ, 2008
- Statins may aggravate myasthenia gravisMuscle & Nerve, 2008
- Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibresBritish Journal of Pharmacology, 2008
- The Role of Coenzyme Q10 in Statin-Associated MyopathyJournal of the American College of Cardiology, 2007
- Genetic determinants of statin intoleranceLipids in Health and Disease, 2007
- Safety and Efficacy of Statins in AsiansThe American Journal of Cardiology, 2007
- Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environmentCancer Cell, 2005
- Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic PolymorphismsThe Journal of Clinical Pharmacology, 2004
- Myolysis and Acute Renal Failure in a Heart-Transplant Recipient Receiving LovastatinNew England Journal of Medicine, 1988